Genelabs Establishes Six-Member Scientific Advisory Board.
Multi-Disciplinary Board to Support Genelabs' Research Endeavors
REDWOOD CITY, Calif., Dec. 5 /PRNewswire/ --
Genelabs Technologies, Inc. (Nasdaq: GNLB) today announced the establishment of its Scientific Advisory Board, whose members include Charles Cantor, Ph.D., Gary Felsenfeld, Ph.D., John Fried, Ph.D., David A. Stevens, M.D., David E. Wemmer, Ph.D. and Richard J. Whitley, M.D.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990728/GNLBLOGO )
"We are very pleased to have such a distinguished group of scientists advising us regarding our research programs, and expect their guidance and insight to be of enormous benefit," said James A. D. Smith, President and Chief Executive Officer of Genelabs. "Our recently announced collaboration and licensing agreement for Aslera(TM), our potential lupus therapy, allows us to devote significant resources to our research efforts. We look forward to working with our Scientific Advisory Board members in this endeavor."
Ming S. Chen, Ph.D., Genelabs Vice President of Research, commented, "Our Scientific Advisory Board members will contribute significantly to Genelabs' research efforts, specifically in the disciplines of chemistry, virology, molecular biology, microbiology, and gene expression, as well as provide guidance for our overall scientific direction. I am excited to see our proprietary drug discovery technologies being applied to a broad range of therapeutic areas and am very encouraged by the progress made to date, which includes discovery of initial lead compounds that have shown potent broad-spectrum anti-fungal activity and potent anti-bacterial activity, respectively, in cell-based assays."
Dr. Charles Cantor is Chief Scientific Officer of Sequenom, Inc. and was previously the Chair of, and currently Professor in, the Department of Biomedical Engineering and Biophysics biophysics, application of various methods and principles of physical science to the study of biological problems. In physiological biophysics physical mechanisms have been used to explain such biological processes as the transmission of nerve impulses, the muscle and is Director of the Center for Advanced Biotechnology at Boston University. He was also the Director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. Dr. Cantor's distinguished career spans the fields of chemistry, biological chemistry, genetics and bioinformatics. Dr. Cantor has published more than 325 peer-reviewed articles and has also published the first textbook on genomics: "The Science and Technology of the Human Genome Project." An inventor on dozens of patents, including several held by Genelabs, Dr. Cantor has been a scientific consultant to Genelabs for 15 years. He remains active in the Human Genome Project through membership in a number of the project's advisory committees and review boards, has served on the editorial boards of many scientific publications and is a member of numerous commercial, academic and medical boards and councils. Dr. Cantor is a member of the National Academy of Sciences. He received his A.B. from Columbia University and his Ph.D. from the University of California, Berkeley The University of California, Berkeley is a public research university located in Berkeley, California, United States. Commonly referred to as UC Berkeley, Berkeley and Cal .
Dr. Gary Felsenfeld is a recognized leader in the field of molecular biology. His recent research has focused on the relationship between chromatin structure and gene expression. Dr. Felsenfeld holds memberships in many scientific organizations and is a Fellow of the American Association for the Advancement of Science; Fellow of the American Academy of Arts and Sciences; Associate Member, European Molecular Biology Organization; and Member of the National Academy of Sciences. He received his A.B. summa cum laude sum·ma cum lau·de
adv. & adj.
With the greatest honor. Used to express the highest academic distinction: graduated summa cum laude; a summa cum laude graduate. in Biochemical Sciences from Harvard College and his Ph.D. in Physical Chemistry from California Institute of Technology California Institute of Technology, at Pasadena, Calif.; originally for men, became coeducational in 1970; founded 1891 as Throop Polytechnic Institute; called Throop College of Technology, 1913–20. . Dr. Felsenfeld was a Postdoctoral Fellow in Quantum Chemistry at Oxford University, has published nearly 200 scientific papers and has served on the editorial boards of more than 10 major scientific publications.
Dr. John Fried is currently President of Fried and Company, Inc., consulting for biotechnology companies. He was most recently Vice Chairman of the Board of Directors of Syntex Corporation and President of Syntex Research. Dr. Fried joined Syntex Research in 1964 as the Department Head of the company's Institute of Organic Chemistry. He held a number of both research and business positions during his 30 years in the Syntex organization. Dr. Fried received both his A.B. and Ph.D. from Cornell University in Organic Chemistry and was a Post Doctoral Fellow at Columbia University in the laboratory of Professor Gilbert Stork. Dr. Fried is a Fellow of the American Association for the Advancement of Science and received the Inventor of the Year Award for naproxen. He has authored more than 80 scientific publications and holds more than 200 U.S. patents.
Dr. David Stevens is Professor and Associate Chief of the Division of Infectious Diseases and Geographic Medicine at Stanford University. He is President Elect of the California Institute for Medical Research, where he is also Director of Clinical Laboratories and Principal Investigator of the Infectious Disease Research Laboratory. At Santa Clara County-Valley Medical Center, Dr. Stevens is Chief of the Division of Infectious Diseases, where he is also Co-director of the Microbiology Laboratory and Hospital Epidemiologist. He received his B.A. from Cornell University and his M.D. from the University of Rochester The University of Rochester (UR) is a private, coeducational and nonsectarian research university located in Rochester, New York. The university is one of 62 elected members of the Association of American Universities. . The 1999 recipient of the Rhoda Benham Medal from the Medical Mycology Society of the Americas, Dr. Stevens was elected to Fellowships in the American College of Physicians; Infectious Disease Society of America; and the American Academy of Microbiology. He is the author of more than 450 papers, articles and book chapters.
Dr. David Wemmer is Professor in the Department of Chemistry at the University of California, Berkeley (UC Berkeley), where he has been on the faculty for 15 years. In addition, he is a Faculty Associate in the Structural Biology Division of the Lawrence Berkeley Laboratory. Dr. Wemmer is currently Director of the National Tritium Labelling Facility (an NIH "Not invented here." See digispeak.
NIH - The United States National Institutes of Health. Research Resource) and is the recipient of many awards and honors; among them most recently is the Miller Research Professor, UC Berkeley. He received his B.S. in Chemistry from the University of California, Davis The University of California, Davis, commonly known as UC Davis, is one of the ten campuses of the University of California, and was established as the University Farm in 1905. and his Ph.D. from UC Berkeley. Dr. Wemmer has served on the editorial boards of a number of scientific publications including "Macromolecular mac·ro·mol·e·cule
A very large molecule, such as a polymer or protein, consisting of many smaller structural units linked together. Also called supermolecule. Structures" and the "Journal of Bimolecular bi·mo·lec·u·lar
Relating to, consisting of, or affecting two molecules.
bimo·lec NMR NMR: see magnetic resonance. ." In addition, he is an Associate Editor of Biopolymers and Editor of "Biopolymers
Nucleic Acids." He is also Chairman of the Scientific Advisory Board of Carta Proteomics, Inc.
Dr. Richard Whitley is Professor of Pediatrics, Microbiology and Medicine; Director, Division of Pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children.
Of or relating to pediatrics. Infectious Diseases; Vice-Chairman of the Department of Pediatrics; and Scientist, Cancer Research and Training Center at the University of Alabama at Birmingham. He holds the 2000 Loeb Eminent Scholar Chair in Pediatrics; is Associate Director for Clinical Studies, Center for AIDS Research; and is on the Faculty of the Gene Therapy Center. Dr. Whitley has been on the faculty of the University of Alabama at Birmingham since 1976, previously was a Fellow in the Department of Pediatrics and completed both his pediatric internship and residency there. He has served on the editorial boards of 17 major medical and scientific publications and is currently the Editor of "Antiviral Research." In addition, Dr. Whitley has authored several hundred papers and book chapters and is the recipient of numerous honors and awards. He received his B.S. in Chemistry from Duke University and his M.D. from the George Washington University School of Medicine.
Genelabs Technologies, Inc. is a biopharmaceutical company engaged in the discovery and development of a new class of pharmaceutical products that selectively regulate gene expression or inactivate pathogens by binding directly to DNA DNA: see nucleic acid.
or deoxyribonucleic acid
One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. or RNA RNA: see nucleic acid.
in full ribonucleic acid
One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic , the fundamental material of genes. By acting directly on the genetic material, Genelabs' technology can be applicable to a wide range of therapeutic applications including diseases such as cancer and autoimmune disorders and infectious diseases caused by bacteria and viruses. Apart from its research, the company has a near-term product opportunity in Aslera(TM) (GL701), which has completed two Phase III clinical trials for systemic lupus erythematosus Systemic Lupus Erythematosus Definition
Systemic lupus erythematosus (also called lupus or SLE) is a disease where a person's immune system attacks and injures the body's own organs and tissues. Almost every system of the body can be affected by SLE. (SLE SLE systemic lupus erythematosus.
systemic lupus erythematosus
Systemic lupus erythematosus (SLE) ). Genelabs is seeking U.S. FDA approval of Aslera(TM) as a new treatment for women with SLE.
NOTE: Except for historical information, the statements in this news release are forward-looking and are subject to uncertainties and risks that could cause actual results to differ materially from the statements made. Uncertainties and risks include, without limitation, whether the results of the company's clinical trials of Aslera(TM) and other supporting information will be sufficient to support the approval of Aslera(TM) by FDA; delays regarding the regulatory approval process including the timing and scope of approval received, if any; uncertainties and risks regarding market acceptance of Aslera(TM) as a treatment for SLE; the early stage of Genelabs' research programs and the company's ability to produce products from its research; the validity, scope and enforceability of patents related to the company's technologies; the company's capital requirements and history of operating losses; and uncertainties and risks regarding the company's ability to consummate strategic or corporate partner transactions on favorable terms or at all. The active ingredient in Aslera(TM) is prasterone, the synthetic equivalent of the androgenic hormone dehydroepiandrosterone (DHEA DHEA dehydroepiandrosterone.
n dehydroepiandrosterone, a hormone precursor, exists naturally in yams. ). Products containing DHEA are currently being marketed by others as dietary supplements. The company has not submitted applications for regulatory review outside the U.S. In addition, neither U.S. nor foreign regulatory authorities has made a determination as to the safety or efficacy of Aslera(TM) for SLE. Please see the information appearing in the company's filings with the Securities and Exchange Commission for more discussion regarding these uncertainties and risks and those associated with the company's research programs, early stage of development and other risks which may affect the company. The company does not undertake any obligation to update these forward-looking statements to reflect events or circumstances after the date of this release.
Genelabs' press releases are available by fax 24 hours a day at no charge by calling PR Newswire's Company News On-Call at 800-758-5804, extension 115419. They are also available on the Internet at http://www.genelabs.com and http://www.prnewswire.com .
CONTACT: Matthew M. Loar, Vice President, Finance of Genelabs Technologies, Inc., 650-562-1424.